NIAID Banner Logo Image

HBV Citations List: December, 2021

Literature Citations

1. Therapeutic Potential of Tea Tree Oil for Tungiasis. Abrha, S., W. Tesfaye, and J. Thomas. American Journal of Tropical Medicine and Hygiene, 2021. 105(5): p. 1157-1162. PMID[34731831]. PMCID[PMC8592176].
[PubMed]. HBV_12_2021.

2. Chinese Patent Medicine Liuweiwuling Tablet Had Potent Inhibitory Effects on Both Wild-type and Entecavir-resistant Hepatitis B Virus (HBV) in Vitro and Effectively Suppressed HBV Replication in Mouse Model. Ge, F.L., L.L. Si, Y. Yang, Y.H. Li, Z.L. Lv, W.H. Liu, H. Liao, J. Wang, J. Zou, L. Li, H. Li, Z.L. Zhang, J.B. Wang, X.C. Lu, D.P. Xu, Z.F. Bai, Y. Liu, and X.H. Xiao. Frontiers in Pharmacology, 2021. 12: 756975. PMID[34776974]. PMCID[PMC8578813].
[PubMed]. HBV_12_2021.

3. JNJ-64794964 (AL-034/TQ-A3334), a TLR7 Agonist, Induces Sustained anti-HBV Activity in AAV/HBV Mice Via Non-cytolytic Mechanisms. Herschke, F., C. Li, R. Zhu, Q. Han, Q. Wu, Q. Lu, E. Barale-Thomas, S. De Jonghe, T.I. Lin, and A. De Creus. Antiviral Research, 2021. 196: 105196. PMID[34718044].
[PubMed]. HBV_12_2021.

4. Inhibition of Hepatitis B Virus Infection by Bile acid Derivatives. Ito, K., A. Okumura, S. Nishimura, M. Jin, M. Iwamoto, K. Watashi, T. Wakita, and M. Yoneda. Hepatology, 2021. 74: p. 510A-510A. ISI[000707188002242].
[WOS]. HBV_12_2021.

5. SBT8230, an Asgr1-directed TLR8 Immunotac Therapeutic for the Treatment of Chronic Hepatitis B Virus, Demonstrates Favorable Preclinical Tolerability with Liver-localized Activity. Jang, G., R. DuBose, M. Comeau, E. Hay, M. Childs, D. Purdy, J.R. Chang, J. Adamo, L. Bogatzki, J. Bannink, B. Stevens, M. Daugherty, R. Carillo, L.Q. Fan, B. Setter, H.Y. Xu, S. Natarajan, P. Tan, Y. Latchman, S. Smith, V. Odegard, and P. Baum. Hepatology, 2021. 74: p. 518A-519A. ISI[000707188002256].
[WOS]. HBV_12_2021.

6. Design, Synthesis and Evaluation of Heteroaryldihydropyrimidine Analogues Bearing Spiro Ring as Hepatitis B Virus Capsid Protein Inhibitors. Ma, Y., S. Zhao, Y. Ren, S. Cherukupalli, Q. Li, M.E. Woodson, D.P. Bradley, J.E. Tavis, X. Liu, and P. Zhan. European Journal of Medicinal Chemistry, 2021. 225: p. 113780. PMID[34438123].
[PubMed]. HBV_12_2021.

7. Novel anti-HBV Combination Treatment Using CRISPR/Cas9 Targeting HBV Genome and Suppression of NHEJ-mediated DNA Repair. Murai, K., T. Kodama, H. Hikita, J. Sung, A. Shimoda, M. Fukuoka, S. Shigeno, K. Fukutomi, Y. Tahata, Y. Makino, R. Yamada, R. Sakamori, T. Tatsumi, and T. Takehara. Hepatology, 2021. 74: p. 62A-63A. ISI[000707188000093].
[WOS]. HBV_12_2021.

8. Besifovir dipivoxil maleate: A Novel Antiviral Agent with Low Toxicity and High Genetic Barriers for Chronic Hepatitis B. Song, J.E. and J.Y. Park. Expert Opinion on Pharmacotherapy, 2021. 22(18): p. 2427-2433. PMID[34392744].
[PubMed]. HBV_12_2021.

9. Preclinical Characterization of ABI-4334, a Novel, Highly Potent Core Inhibitor for the Treatment of Chronic Hepatitis B Virus Infection. Xu, X., M. Shen, L. Guo, A. Tang, N. Unchwaniwala, T.J. Heckrodt, M. Zhong, M. Walker, M. Perron, W.E. Delaney, and K. Kitrinos. Hepatology, 2021. 74(6): p. 1394A-1395A. ISI[000727360100084].
[WOS]. HBV_12_2021.

10. STING Agonist Mediates Antiviral Effects in AAV-HBV Mouse Model. Zhang, M.Y. and J.Q. Niu. Hepatology, 2021. 74: p. 520A-521A. PMID[000707188002259].
[WOS]. HBV_12_2021.

Patent Citations

This month, no relevant HBV patents were identified.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: April 2023